Clinical trials: Vancomycin
- Drug or intervention Vancomycin
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Bacterial Conjunctivitis
Safety and Efficacy of Vancomycin Ophthalmic Ointment in Patients With Moderate to Severe Bacterial Conjunctivitis
This is a Phase 3 study to evaluate the safety and efficacy of a vancomycin hydrochloride ophthalmic ointment dosed 4 times daily for 7 days compared to placebo (vehicle) in patients with moderate to severed Gram-positive…
- Trial name
- NCT02432807
- Testing
- Vancomycin 1.1%
- Where
- 16 sites in United States
- Volunteers
- 303 people
- Sponsor
- Kurobe LLC
Vancomycin Resistance Enterococcus Faecium
Zyvox (Linezolid) Special Investigation For Vancomycin-Resistant Enterococci (VRE)
To collect the efficacy and safety information in subjects who have been treated with Zyvox (linezolid) for vancomycin resistance Enterococcus faecium infection for their appropriate use in daily practice.
- Trial name
- NCT01224626
- Testing
- Zyvox (linezolid)
- Volunteers
- 41 people
- Sponsor
- Pfizer
Bacteremia
Safety & Efficacy of Daptomycin Versus Standard of Care (SOC) in 1 - 17 Year Olds With Staphylococcus Aureus Bacteremia (MK-3009-005)
The intent of this study is to describe the safety and efficacy of daptomycin versus standard of care (SOC) in pediatric participants aged 1-17 years with bacteremia caused by Staphylococcus aureus (S. aureus).
- Trial name
- NCT01728376
- Testing
- Daptomycin, Comparator
- Volunteers
- 82 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Acute Hematogenous Osteomyelitis
Safety and Efficacy Study of Daptomycin Compared to Active Comparator in Pediatric Participants With Acute Hematogenous Osteomyelitis (AHO) (MK-3009-006)
The purpose of the study is to determine whether daptomycin is effective and safe in the treatment of pediatric participants with AHO when compared to vancomycin (or equivalent) or nafcillin (or β-lactam equivalent).
- Trial name
- NCT01922011
- Testing
- Daptomycin, Vancomycin (or equivalent), Nafcillin (or equivalent)
- Volunteers
- 149 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Cystic Fibrosis
Efficacy and Safety Study of AeroVanc for the Treatment of Persistent MRSA Lung Infection in Cystic Fibrosis Patients
The purpose of this study is to determine whether AeroVanc treatment is safe and effective in reducing the number of MRSA colony forming units in the lungs of cystic fibrosis patients.
- Trial name
- NCT01746095
- Testing
- Vancomycin hydrochloride inhalation powder
- Where
- 38 sites in United States
- Volunteers
- 87 people
- Sponsor
- Savara Inc.
Pouchitis
A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis
When some people have their large bowel removed, a surgeon can make a "pouch" from part of the small bowel to connect it to the back passage (anus). Pouchitis is when the pouch becomes inflamed (swollen) or infected.
- Trial name
- NCT06443502
- Testing
- Vedolizumab, Concomitant Antibiotic Therapy
- Where
- 14 sites in Belgium, Croatia and 6 more
- Volunteers
- 30 people
- Sponsor
- Takeda
Pneumonia, Pneumonia in Children
Assessing Role of Probiotics in Children Aged 6-36 Months Treated for Pneumonia
The main questions this study aims to answer are: Does using probiotic nasal spray (LiveSpo Navax containing Bacillus subtilis and Bacillus clausii, 1x10^9 CFU/mL), with or without oral probiotics (LiveSpo Pregmom containing…
- Trial name
- NCT07399717
- Testing
- Navax, Navax-PregMom
- Where
- Vietnam
- Volunteers
- 330 people
- Sponsor
- Anabio R&D
Clostridium Difficile Infection
Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)
The primary objectives of this study are to evaluate the pharmacokinetics (PK), safety, and tolerability of bezlotoxumab (MK-6072) in children aged 1 to <18 years of age with a confirmed diagnosis of Clostridium difficile…
- Trial name
- MODIFY III (NCT03182907)
- Testing
- Bezlotoxumab, Antibacterial drug treatment (ABD)
- Where
- 75 sites in United States, Argentina and 15 more
- Volunteers
- 148 people
- Sponsor
- Merck Sharp & Dohme LLC
Clostridium Difficile Infection
Comparison of Cadazolid Versus Vancomycin in Children With Clostridium Difficile-associated Diarrhea (CDAD)
Cadazolid has demonstrated activity against a bacteria named Clostridium difficile in animal studies. The results of a first study conducted in adult patients have suggested efficacy of the new antibiotic, cadazolid, in the…
- Trial name
- NCT03105479
- Testing
- Cadazolid, Vancomycin capsule, Vancomycin solution
- Where
- 20 sites in United States, Belgium and 7 more
- Volunteers
- 1 people
- Sponsor
- Actelion
Bacterial Infections
New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)
This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)
- Trial name
- NCT00035854
- Testing
- Zyvox® / Linezolid
- Where
- 21 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pfizer
Bacterial Infections, Gram-Positive Bacterial Infections
Antibiotic Treatment for Infections of Short Term In-dwelling Vascular Catheters Due to Gram Positive Bacteria
This study will treat patients who have a short term central catheter that is thought to be infected with a specific bacteria (gram positive bacteria)
- Conditions
- Bacterial Infections, Gram-Positive Bacterial Infections, Bacteremia
- Trial name
- NCT00037050
- Testing
- Linezolid, Vancomycin, Oxacillin
- Volunteers
- 739 people
- Sponsor
- Pfizer
Infections, Pediatrics
Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Skin Infections
This is a study of safety, effectiveness, blood levels and tolerance of Ceftaroline fosamil in children with skin infections receiving antibiotic therapy in the hospital.
- Trial name
- NCT01400867
- Testing
- Ceftaroline fosamil, Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam, Cephalexin or Clindamycin or Linezolid
- Where
- 71 sites in United States, Argentina and 8 more
- Volunteers
- 163 people
- Sponsor
- Forest Laboratories
Skin Diseases, Infectious
Safety and Efficacy Study of Daptomycin in Pediatric Participants (1 to 17 Years-old) With Skin and Skin Structure Infections
This is a multi-center, evaluator-blinded, randomized, comparative study designed to assess the safety, efficacy, and pharmacokinetics (PK) of daptomycin in pediatric subjects ages 1 to 17 years, inclusive, with complicated skin…
- Trial name
- NCT00711802
- Testing
- Daptomycin, Standard of Care (SOC)
- Where
- 30 sites in United States, India and 1 more
- Volunteers
- 396 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Febrile Neutropenia
Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection
This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).
- Trial name
- NCT00035425
- Testing
- linezolid, vancomycin
- Where
- 40 sites in United States, Argentina and 8 more
- Volunteers
- 120 people
- Sponsor
- Pfizer
Clostridium Infections, Diarrhea
Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) (MK-5119-018)
This is a comparative study to investigate the safety and efficacy of fidaxomicin versus vancomycin in subjects with Clostridium difficile-Associated Diarrhea (CDAD).
- Trial name
- NCT00314951
- Testing
- Fidaxomicin, Vancomycin
- Volunteers
- 629 people
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
MRSA, Cystic Fibrosis
AeroVanc in the Treatment of Methicillin-resistant Staphylococcus Aureus Infection in Patients With Cystic Fibrosis
This is a multi-center, randomized phase III study to evaluate the clinical effectiveness of AeroVanc in persistent methicillin-resistant Staphylococcus aureus (MRSA) infection in patients with cystic fibrosis (CF).
- Trial name
- NCT03181932
- Testing
- Vancomycin inhalation powder
- Where
- 71 sites in United States, Canada
- Volunteers
- 188 people
- Sponsor
- Savara Inc.
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections in children, aged birth to 17 years (inclusive), known or suspected to be caused by…
- Conditions
- Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
- Trial name
- NCT02814916
- Testing
- Dalbavancin, Vancomycin, Oxacillin
- Where
- 84 sites in United States, Argentina and 18 more
- Volunteers
- 199 people
- Sponsor
- AbbVie
Clostridium Infections, Diarrhea
PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD)
This is a comparative study to investigate the safety and efficacy of PAR-101/OPT-80 (fidaxomicin) versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).
- Trial name
- NCT00468728
- Testing
- PAR-101/OPT-80, Vancomycin
- Where
- 116 sites in United States, Belgium and 7 more
- Volunteers
- 535 people
- Sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Skin Diseases, Infectious, Skin Diseases, Bacterial
Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)
The purpose of the study is to compare the safety of intravenous (IV) and/or oral 6-day 200 mg tedizolid phosphate with 10-day comparator in participants 12 to <18 years with cSSTI.
- Trial name
- NCT02276482
- Testing
- Tedizolid Phophate, Antibiotic comparator, Aztreonam
- Volunteers
- 120 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Community-acquired Pneumonia (CAP), Hospital-acquired Pneumonia (HAP)
Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
This was a study of the safety and efficacy of ceftobiprole medocaril compared with intravenous (IV) standard-of-care cephalosporin treatment with or without vancomycin in pediatric patients with either hospital-acquired…
- Trial name
- NCT03439124
- Testing
- ceftobiprole medocaril, IV standard-of-care cephalosporin
- Where
- 19 sites in Bulgaria, Georgia and 2 more
- Volunteers
- 138 people
- Sponsor
- Basilea Pharmaceutica